Akero Therapeutics, Inc. (AKRO)
| Market Cap | 4.50B +110.4% |
| Revenue (ttm) | n/a |
| Net Income | -292.82M |
| EPS | -3.74 |
| Shares Out | 82.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,312,254 |
| Open | 54.52 |
| Previous Close | n/a |
| Day's Range | 54.37 - 54.83 |
| 52-Week Range | 21.34 - 58.40 |
| Beta | -0.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 7, 2025 |
About AKRO
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell ... [Read more]
Financial Performance
Financial StatementsNews
Novo Nordisk has completed its acquisition of Akero Therapeutics
Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq: AKRO) today announced that Novo Nordisk's acquisition of Akero, announc...
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
PHILADELPHIA , Nov. 12, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its...
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compe...
Top Stock Movers Now: Delta Air Lines, PepsiCo, Akero Therapeutics, and More
Major U.S. equities indexes pulled back Thursday after the S&P 500 and Nasdaq set fresh all-time highs. The Dow Jones Industrial Average, S&P 500, and Nasdaq all were lower at midday.
Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug
Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's ...
Akero Therapeutics soars after Novo Nordisk set for $5.2B cash acquisition
Novo Nordisk said on Thursday it would acquire Akero Therapeutics for up to $5.2 billion in cash, marking a significant push into treatments for fatty liver disease as the Danish drugmaker seeks to br...
Akero Therapeutics Stock Soars on Novo Nordisk Deal.
Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of Efruxifermin - it's treatment for fatty liver disease.
Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease
Novo Nordisk, the Danish drugmaker behind Ozempic and other weight-loss drugs, said it's paying up to $5.2 billion to buy Akero Therapeutics, a biotech with a drug in a late-stage trial to treat a fat...
Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion
Novo said the acquisition of would contribute to its strategy to develop medicines for people living with diabetes, obesity and their associated comorbidities.
Novo Nordisk to buy Akero for up to $5.2 billion as new CEO bets on liver drug candidate
Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to gain access to a promising liver disease drug candidate, in the first major deal by the Danish drugma...
Novo Nordisk buys Akero Therapeutics in the US
Danish drugmaker Novo Nordisk said on Thursday it had agreed to buy United States based Akero Therapeutics, a clinical-stage company developing innovative treatments for patients with serious metaboli...
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero's Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif., Oct. ...
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
Bagsværd, Denmark, 9 October, 2025 – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Akero Therapeutics, Inc. (Akero), a publicly held clinical-stage company de...
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH Results support potential of efruxifermin (EFX) to reduce risk of fib...
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant...
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabol...
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX)
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabol...
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at E...
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabol...